Dear Sir, Please find Newspaper Advertisement for the Unaudited Financial Results for the quarter and nine months ended on 31.12.2025.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Omkar Pharmachem Ltd submitted a newspaper publication of its unaudited financial results for the quarter ended December 31, 2025 (Q3 FY26) and the nine months ended on that date. For Q3 FY26, total income from operations stood at Rs. 10.50 lakh, down from Rs. 13.72 lakh in Q3 FY25. Net profit after tax came in at Rs. 2.95 lakh, a sharp drop of around 65% from Rs. 8.49 lakh in the year-ago quarter. Basic and diluted EPS for the quarter was Rs. 0.0293 versus Rs. 0.0842 in Q3 FY25. For the nine-month period (9M FY26), the company posted a net profit after tax of Rs. 10.68 lakh on total income of Rs. 37.94 lakh. The results were reviewed by the audit committee and approved by the Board on February 14, 2026. Equity share capital remained at Rs. 1,008.37 lakh.
Both top-line and bottom-line came in significantly lower compared to the same quarter last year, signalling weak quarterly performance that may draw negative attention from investors focused on growth.